We saw evidence for JAK use in GCA this conference… what about IL-1 inhibition?

Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt

NO difference in relapse rate at 26, 52 wks despite addition of Anakinra

@RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG